{"name":"Fundación Universitaria de Ciencias de la Salud","slug":"fundaci-n-universitaria-de-ciencias-de-la-salud","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Fada Remifentanilo","genericName":"Fada Remifentanilo","slug":"fada-remifentanilo","indication":"Intravenous analgesia and sedation during general anesthesia","status":"marketed"},{"name":"Remifentanyl, Ultiva®","genericName":"Remifentanyl, Ultiva®","slug":"remifentanyl-ultiva","indication":"Intraoperative analgesia during general anesthesia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Remifentanil Laboratorios Chalver de Colombia S.A.","genericName":"Remifentanil Laboratorios Chalver de Colombia S.A.","slug":"remifentanil-laboratorios-chalver-de-colombia-s-a","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Fada Remifentanilo","genericName":"Fada Remifentanilo","slug":"fada-remifentanilo","phase":"marketed","mechanism":"Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.","indications":["Intravenous analgesia and sedation during general anesthesia","Analgesia in mechanically ventilated patients in intensive care settings"],"catalyst":""},{"name":"Remifentanil Laboratorios Chalver de Colombia S.A.","genericName":"Remifentanil Laboratorios Chalver de Colombia S.A.","slug":"remifentanil-laboratorios-chalver-de-colombia-s-a","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Remifentanyl, Ultiva®","genericName":"Remifentanyl, Ultiva®","slug":"remifentanyl-ultiva","phase":"marketed","mechanism":"Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.","indications":["Intraoperative analgesia during general anesthesia","Sedation and analgesia in mechanically ventilated patients in intensive care settings"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}